NEW YORK ( TheStreet) -- Cardiome Pharma Corp (Nasdaq: CRME) has been downgraded by TheStreet Ratings from hold to sell. The company's weaknesses can be seen in multiple areas, such as its generally disappointing historical performance in the stock itself and deteriorating net income.

Highlights from the ratings report include:
  • CARDIOME PHARMA CORP has exprienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. This company has not demonstrated a clear trend in earnings over the past two years, making it difficult to accurately predict earnings for the coming year. During the past fiscal year, CARDIOME PHARMA CORP turned its bottom line around by earning $0.58 versus -$0.02 in the prior year.
  • CRME, with its very weak revenue results, has greatly underperformed against the industry average of 0.5%. Since the same quarter one year prior, revenues plummeted by 98.3%. Weakness in the company's revenue seems to have hurt the bottom line, decreasing earnings per share.
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Pharmaceuticals industry. The net income has significantly decreased by 145.9% when compared to the same quarter one year ago, falling from $15.47 million to -$7.10 million.
  • Despite any intermediate fluctuations, we have only bad news to report on this stock's performance over the last year: it has tumbled by 37.31%, worse than the S&P 500's performance. Consistent with the plunge in the stock price, the company's earnings per share are down 146.15% compared to the year-earlier quarter. Despite the heavy decline in its share price, this stock is still more expensive (when compared to its current earnings) than most other companies in its industry.

Cardiome Pharma Corp., a life sciences company, engages in developing proprietary drugs to treat or prevent cardiovascular and other diseases. The company has a P/E ratio of 26, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7. Cardiome has a market cap of $317.9 million and is part of the health care sector and drugs industry. Shares are down 20.4% year to date as of the close of trading on Thursday.

You can view the full Cardiome Ratings Report or get investment ideas from our investment research center.
null